Haematologica (May 2023)

Clinical and molecular correlates of somatic and germline <i>DDX41</i> variants in patients and families with myeloid neoplasms

  • Talha Badar,
  • Ahmad Nanaa,
  • James M. Foran,
  • David Viswanatha,
  • Aref Al-Kali,
  • Terra Lasho,
  • Christy Finke,
  • Hassan B Alkhateeb,
  • Rong He,
  • Naseema Gangat,
  • Mithun Shah,
  • Ayalew Tefferi,
  • Abhishek A Mangaonkar,
  • Mark R Litzow,
  • Laura J. Ongie,
  • Timothy Chlon,
  • Alejandro Ferrer,
  • Mrinal M. Patnaik

DOI
https://doi.org/10.3324/haematol.2023.282867
Journal volume & issue
Vol. 108, no. 11

Abstract

Read online

The diagnosis of germline predisposition to myeloid neoplasms (MN) secondary to DDX41 variants is currently hindered by the long latency period, variable family histories and the frequent occurrence of DDX41 variants of uncertain significance (VUS). We reviewed 4,524 consecutive patients who underwent targeted sequencing for suspected or known MN and analyzed the clinical impact and relevance of DDX41VUS in comparison to DDX41path variants. Among 107 patients (44 [0.9%] DDX41path and 63 DDX41VUS [1.4%; 11 patients with both DDX41path and DDX41VUS]), we identified 17 unique DDX41path and 45 DDX41VUS variants: 24 (23%) and 77 (72%) patients had proven and presumed germline DDX41 variants, respectively. The median age was similar between DDX41path and DDX41VUS (66 vs. 62 years; P=0.41). The median variant allele frequency (VAF) (47% vs. 48%; P=0.62), frequency of somatic myeloid co-mutations (34% vs 25%; P= 0.28), cytogenetic abnormalities (16% vs. 12%; P=>0.99) and family history of hematological malignancies (20% vs. 33%; P=0.59) were comparable between the two groups. Time to treatment in months (1.53 vs. 0.3; P=0.16) and proportion of patients progressing to acute myeloid leukemia (14% vs. 11%; P=0.68), were similar. The median overall survival in patients with high-risk myelodysplastic syndrome/acute myloid leukemia was 63.4 and 55.7 months in the context of DDX41path and DDX41VUS, respectively (P=0.93). Comparable molecular profiles and clinical outcomes among DDX41path and DDX41VUS patients highlights the need for a comprehensive DDX41 variant interrogation/classification system, to improve surveillance and management strategies in patients and families with germline DDX41 predisposition syndromes.